Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)

    Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. “Oncology Frontier” invited…

    2024.08.09
  • 2024 COMB丨Dr. Tao Sun: Progress in HER2+ EBC Treatment—De-escalation Therapy and the Prospects of ctDNA Application

    In recent years, the field of breast cancer treatment has seen a series of innovative research advancements, particularly in the treatment of HER2+ early breast cancer (EBC). Strategies such as “de-escalation,” “chemotherapy-free,” and “precision treatment” have become hot topics. At the 7th Precision Diagnosis and Treatment of Tumors and the 10th Individualized Treatment of Breast…

    2024.08.09
  • 🎙️ ASCO-GU Interview | Dr. Neal D. Shore: Examining Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study. 🔍

    2024.08.09
  • ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival

    The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a…

    2024.08.09
  • EHA International Perspective | Professor Thierry Facon: Major Advances in Multiple Myeloma Treatment—Insights from the IMROZ Study

    Despite significant improvements in the survival of multiple myeloma (MM) patients over the past two decades, thanks to the emergence of new drugs and therapies, the prognosis for those not eligible for bone marrow transplantation remains relatively poor. Therefore, there is an urgent need to explore new treatment options to improve their outcomes. At the…

    2024.08.09
  • 🎙️ Exciting insights from Dr. Andrea B. Apolo of the National Cancer Institute’s Genitourinary Malignancies Branch in our latest Hematology Frontier interview! 🌟

    2024.08.09
  • EHA Global Insights 🌍 | Dr. Michael Wang Interprets the Latest Results from the ECHO Clinical Trial 🔬✨

    2024.08.09
  • Fadi Haddad’s interview with Oncology Frontier. 🎙️🩺

    2024.08.09
«previous next»
Recent Posts
  • CSCO 2026 | Professor Yanxia Shi: Extending Endocrine-Based Treatment — CDK2/4/6 Inhibition Offers a Therapeutic Option for Mutation-Negative Patients After CDK4/6 Inhibitor Therapy
  • CSCO 2026 | Professor Biyun Wang: From Stratification to Precision — Treatment Strategies After CDK4/6 Inhibitor Resistance and the Clinical Positioning of the CDK2/4/6 Inhibitor Kermoxili
  • CSCO International Perspectives | Professor Kun Wang in Conversation With Professor Pier Paolo Berton Giachetti: From Experience to Evidence — The Path Toward Precision Treatment in Early HER2-Positive Breast Cancer
  • ESMO Preview | Professor Yongmei Yin: A New Breakthrough in HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy
  • Personalized mRNA Vaccine Plus Pembrolizumab Reduces Recurrence and Metastasis in Melanoma
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top